GLICLAZIDE LUPIN MR gliclazide 60 mg modified release tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

gliclazide lupin mr gliclazide 60 mg modified release tablet blister pack

lupin australia pty limited - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; hypromellose; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

SITAGLIPTIN LUPIN sitagliptin (as hydrochloride monohydrate) 100 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sitagliptin lupin sitagliptin (as hydrochloride monohydrate) 100 mg tablet blister pack

lupin australia pty limited - sitagliptin hydrochloride monohydrate, quantity: 113.373 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; hyprolose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin lupin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,? monotherapy when metformin is considered inappropriate due to intolerance; or,? in combination with other antihyperglycaemic agents, including insulin.,(see section 5.1 pharmacodynamic properties - clinical trials and section 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.)

SITAGLIPTIN LUPIN sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sitagliptin lupin sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack

lupin australia pty limited - sitagliptin hydrochloride monohydrate, quantity: 56.686 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; microcrystalline cellulose; hyprolose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin lupin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,? monotherapy when metformin is considered inappropriate due to intolerance; or,? in combination with other antihyperglycaemic agents, including insulin.,(see section 5.1 pharmacodynamic properties - clinical trials and section 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.)

SITAGLIPTIN LUPIN sitagliptin (as hydrochloride monohydrate) 25 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sitagliptin lupin sitagliptin (as hydrochloride monohydrate) 25 mg tablet blister pack

lupin australia pty limited - sitagliptin hydrochloride monohydrate, quantity: 28.343 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: hyprolose; calcium hydrogen phosphate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin lupin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,? monotherapy when metformin is considered inappropriate due to intolerance; or,? in combination with other antihyperglycaemic agents, including insulin,(see section 5.1 pharmacodynamic properties - clinical trials and section 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.)